Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Corbus Pharmaceuticals (GB:0SZI)
LSE:0SZI
RESEARCH TOOLSreports
Corbus Pharmaceuticals (0SZI) Share Price & Analysis
0 Followers
0SZI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.12 - $49.65
Previous Close$38.36
Volume423.00
Average Volume (3M)3.66K
Market Cap
$411.75M
Enterprise Value$411.73M
Total Cash (Recent Filing)$20.91M
Total Debt (Recent Filing)$20.88M
Price to Earnings (P/E)N/A
Beta0.99
Next Earnings
May 09, 2024EPS Estimate
-$1.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding10,493,108
10 Day Avg. Volume109
30 Day Avg. Volume3,661
Standard Deviation0.25
R-Squared0.12
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)-59.63
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-17.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-11.99
Forecast
1Y Price Target
$55.00Price Target Upside46.74% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Corbus Pharmaceuticals News
PremiumCompany Announcements
Corbus Pharmaceuticals Executives Sign New Employment Deals
0SZI FAQ
What was Corbus Pharmaceuticals’s price range in the past 12 months?
Corbus Pharmaceuticals lowest share price was $3.12 and its highest was $49.65 in the past 12 months.
What is Corbus Pharmaceuticals’s market cap?
Currently, no data Available
When is Corbus Pharmaceuticals’s upcoming earnings report date?
Corbus Pharmaceuticals’s upcoming earnings report date is May 09, 2024 which is in 16 days.
How were Corbus Pharmaceuticals’s earnings last quarter?
Corbus Pharmaceuticals released its earnings results on Mar 12, 2024. The company reported -$1.81 earnings per share for the quarter, beating the consensus estimate of -$2.155 by $0.345.
Is Corbus Pharmaceuticals overvalued?
According to Wall Street analysts Corbus Pharmaceuticals’s price is currently Undervalued.
Does Corbus Pharmaceuticals pay dividends?
Corbus Pharmaceuticals does not currently pay dividends.
What is Corbus Pharmaceuticals’s EPS estimate?
Corbus Pharmaceuticals’s EPS estimate is -$1.09.
How many shares outstanding does Corbus Pharmaceuticals have?
Corbus Pharmaceuticals has 10,493,108 shares outstanding.
What happened to Corbus Pharmaceuticals’s price movement after its last earnings report?
Corbus Pharmaceuticals reported an EPS of -$1.81 in its last earnings report, beating expectations of -$2.155. Following the earnings report the stock price went up 13.56%.
Which hedge fund is a major shareholder of Corbus Pharmaceuticals?
Currently, no hedge funds are holding shares in GB:0SZI
---
Corbus Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$55.00 (46.74% Upside)
$55.00 (46.74% Upside)
Blogger Sentiment
Bullish
GB:0SZI Sentiment 85%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $46.8M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
289.67%
12-Months-Change
Fundamentals
Return on Equity
-341.98%
Trailing 12-Months
Asset Growth
-57.36%
Trailing 12-Months
Company Description
Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded on December 18, 2013 and is headquartered in Norwood, MA.
---
0SZI Stock 12 Months Forecast
Average Price Target
$55.00
▲(46.74% Upside)
Technical Analysis
Corbus Pharmaceuticals
―
Aclaris Therapeutics
―
SAGE Therapeutics
―
Ultragenyx Pharmaceutical
―
MacroGenics
―
Best Analysts Covering 0SZI
1 Year
1 Year Success Rate
2/4 ratings generated profit
1 Year Average Return
+103.33%
reiterated a buy rating 16 days ago
Copying Jeff Jones's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +103.33% per trade.
---